MY-875

MY-875 is a competitive microtubulin polymerization inhibitor with an IC50 value of 0.92 μM. MY-875 inhibits microtubulin polymerization by targeting colchicine binding sites and activates the Hippo pathway. MY-875 induces apoptosis and has anticancer activity[1].

Product Specifications

UNSPSC

12352005

Target

Apoptosis; Microtubule/Tubulin

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/my-875.html

Concentration

10mM

Purity

99.56

Solubility

DMSO : ≥ 250 mg/mL

Smiles

COC1=CC(N(C(/C=C/C)=O)CC2=CC(O)=C(OC)C=C2)=CC(OC)=C1OC

Molecular Formula

C21H25NO6

Molecular Weight

387.43

References & Citations

[1]Jian Song, et al. Discovery of N-benzylarylamide derivatives as novel tubulin polymerization inhibitors capable of activating the Hippo pathway. Eur J Med Chem. 2022 Jul 7;240:114583.